Skip to main content
Fig. 7 | Cell Division

Fig. 7

From: M2I-1 disrupts the in vivo interaction between CDC20 and MAD2 and increases the sensitivities of cancer cell lines to anti-mitotic drugs via MCL-1s

Fig. 7

The regulation of the stabilities of MCL-1, Cyclin A in HeLa cells. a Representative confocal images showing the expressions and distributions of the MCL-1 (green in merged images) in unperturbed HeLa cells at different cell cycle stages as indicated. Cyclin A in red (merged images, Santa Cruz, sc-271682, mouse monoclonal anti-cyclin A (B-8) 1:500 dilutions). These cells were fixed with 4% formamide-PBS solution and stained with a primary anti-Mcl-1 (S-19, Santa Cruz, sc-819) antibody (1:500 dilutions) or anti-Cyclin A (B-8) antibody (Santa Cruz, sc-271682) (1:500 dilutions). DNA was stained with DAPI (blue in merged images). The distributions of the fluorescent signals of Cyclin A throughout the cell cycle used for timing the cell cycle stages for comparison purpose. b Representative confocal images showing the expressions of MCL-1 (green) in nocodazole arrested (top panel) or nocodazole and MG132 arrested (bottom panel) HeLa cells. DNA was stained with DAPI (blue in merged images) and the mitotic status highlighted by staining with the phosphor-histone H3 S-10 antibody (red, Cell signalling, 9706, 1:200 dilutions). HeLa cells were treated with nocodazole or nocodazole + MG132 for 8 h

Back to article page